Blood Testing Startup Sight Diagnostics Reveals Investors in $28 Million Round

The company announced the private issuance in December via shareholder Clal Biotechnology Industries

Blood testing startup S.D. Sight Diagnostics Ltd. has announced additional details regarding its $27.8 series C round, first announced in December via its shareholder Clal Biotechnology Industries Ltd. On Thursday, the company revealed the round was led by Longliv Ventures, a member of multinational health and beauty conglomerate the CK Hutchison Group. Existing investors OurCrowd, Go Capital, and New Alliance Capital also participated.

 

Sight stated it will use the funding for research and development.

 

Blood test (illustration). Photo: Shutterstock